<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03987295</url>
  </required_header>
  <id_info>
    <org_study_id>AL001-2</org_study_id>
    <nct_id>NCT03987295</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)</brief_title>
  <official_title>A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9orf72 Mutations Causative of Frontotemporal Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alector Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alector Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and
      pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation
      causative of frontotemporal dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multicenter, open label study evaluating the safety, tolerability, PK and
      PD of AL001 administered intravenously in participants with a Granulin mutation or C9orf72
      mutation causative of frontotemporal dementia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety and tolerability of AL001: Incidence of adverse events</measure>
    <time_frame>96 weeks</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of AL001</measure>
    <time_frame>96 weeks</time_frame>
    <description>Concentration of AL001 at specified time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) for AL001</measure>
    <time_frame>96 weeks</time_frame>
    <description>Evaluate Cmax for concentration of AL001 at specified time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve concentration (AUC) for AL001</measure>
    <time_frame>96 weeks</time_frame>
    <description>Evaluate AUC for concentration of AL001 at specified time points</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Frontotemporal Dementia</condition>
  <arm_group>
    <arm_group_label>AL001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL001 every 4 weeks for up to 96-weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL001</intervention_name>
    <description>administered via intravenous (IV) infusion once a month</description>
    <arm_group_label>AL001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At screening, female participants must be nonpregnant and nonlactating

          -  In good physical health on the basis of no clinically significant findings from
             medical history, physical examinations (PEs), laboratory tests, ECGs, and vital signs.

          -  Participant is a carrier of a loss of function progranulin gene (GRN) mutation or
             carrier of a hexanucleotide repeat expansion C9orf72 mutation

        Exclusion Criteria:

          -  Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric, human, or humanized antibodies or fusion proteins.

          -  History of alcohol abuse or substance abuse

          -  Participant resides in a skilled nursing facility, convalescent home, or long term
             care facility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Ljubenkov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Lead</last_name>
    <phone>4152315660</phone>
    <phone_ext>372</phone_ext>
    <email>info@alector.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-514-5745</phone>
      <email>lauren.fisher@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Study Coordinator</last_name>
      <phone>415-476-0671</phone>
      <email>hannah.wiest@ucsf.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>507-293-5551</phone>
      <email>Forsberg.leah@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Study Coordinator</last_name>
      <phone>507-284-9295</phone>
      <email>Nelson.Kevin1@mayo.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-662-3596</phone>
      <email>Frewine.Ogbaselase@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Study Coordinator</last_name>
      <phone>215-662-3596</phone>
      <email>Vidya.Chenji@Pennmedicine.upenn.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lawson Health Research Institute, St. Joseph's</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+1-519-685-4292</phone>
      <phone_ext>45635</phone_ext>
      <email>Rokhsana.Mortuza@sjhc.london.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>1620</phone_ext>
      <email>Michael.comishen@sunnybrook.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technical University of Munich</name>
      <address>
        <city>Munchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>49 89 4140 4276</phone>
      <email>Bianca.Bierschneider@mri.tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Study Coordinator</last_name>
      <phone>49 89 4140 4276</phone>
      <email>Julia.Graesel@mri.tum.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0049 731 500 63099</phone>
      <email>karin.graf@uni-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Study Coordinator</last_name>
      <phone>0049 731 500 63099</phone>
      <email>sarah.straub@uni-ulm.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>39 345 457 4826</phone>
      <email>benussialberto@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0031-6-50031924</phone>
      <email>a.eladdouti-elbelhajji@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Study Coordinator</last_name>
      <phone>0031-6-50008263</phone>
      <email>w.degroot.1@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+44 (0) 20 3448 3105</phone>
      <email>drctrialenquiries@ucl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Study Coordinator</last_name>
      <phone>44 203 44 84536</phone>
      <email>joanna.irish@nhs.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

